ARCHIVES

The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year

This article is from The Cancer Letter archive.

Vol. 38 No. 16 | April 20, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Beings Accelerated Review Of R01s That just Miss Payline

March 29, 1996

Two-Point Rise In PSA Signals High-Risk Prostate Cancer

August 26, 2005

ODAC Rejects Temodal for Melanoma After Discussion Of Approval Standards

April 2, 1999

Funding Opportunities: NCI Offers Funds To Develop, Validate Mouse Models

November 20, 1998

In Brief: NCI Holding Up Regional Cooperative Group RFA Until Department Approves New Mechanism

February 27, 1981

BSA Approves Six Concepts

July 19, 2013